#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2018 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "Private Ownership to Fraunhofer Institute SCAI"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "The Biology of Proteostasis in Aging and Disease"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Esther Wollert"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/cf4d8bb88754f036b943b4d94ad96e103dcb7149/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "25784053"}

SET Evidence = "Proteome fidelity is maintained by the protein homeostasis (proteostasis) network (PN), a
multi-compartmental system that coordinatesprotein synthesis, folding, disaggregation, and
degradation (1)."
bp(HBP:Proteostasis) -- bp(MESH:"Protein Biosynthesis")
bp(HBP:Proteostasis) -- bp(GO:"protein folding")
bp(HBP:Proteostasis) -- path(MESH:"Protein Aggregation, Pathological")
bp(HBP:Proteostasis) -- bp(MESH:"Proteolysis")

SET Evidence = " Furthermore, the activity of the PN can be altered permanently
or transiently by development and aging, alterations in physiology, or exposure to
environmental stress (1)."
bp(MESH:"Growth and Development") reg bp(HBP:Proteostasis)
bp(MESH:Aging) reg bp(HBP:Proteostasis)
bp(MESH:"Stress, Physiological") reg bp(HBP:Proteostasis)

SET Evidence = "Molecular chaperones are central to the function of the PN and can be broadly grouped into
the HSP70, HSP90, DNAJ/HSP40, chaperonin/HSP60, and small HSP (sHSP) families (10,
11)."
p(FPLX:HSPA) isA a(MESH:"Molecular Chaperones")
p(FPLX:HSP90) isA a(MESH:"Molecular Chaperones")
p(HGNCGENEFAMILY:"DNAJ (HSP40) heat shock proteins") isA a(MESH:"Molecular Chaperones")
p(HGNC:HSPD1) isA a(MESH:"Molecular Chaperones")
p(FPLX:HSPB) isA a(MESH:"Molecular Chaperones")

SET Evidence = "ATP hydrolysisis essential for the chaperone activity of
HSP70 and HSP90, causing conformational changes that result in substrate binding (11)."
bp(GO:"ATP metabolic process") -> act(p(FPLX:HSPA))
bp(GO:"ATP metabolic process") -> act(p(FPLX:HSP90))

SET Evidence = " As such, HSP70 and HSP90 are central to the process
of triaging proteins for refolding or elimination."
p(FPLX:HSPA) reg bp(GO:"protein folding")
p(FPLX:HSPA) reg bp(MESH:"Proteolysis")
p(FPLX:HSP90) reg bp(GO:"protein folding")
p(FPLX:HSP90) reg bp(MESH:"Proteolysis")

SET Evidence = " Perhaps the
most significant example of this process is that the HSP110 molecular chaperone, long
considered simply a NEF, can catalyze protein disaggregation as part of a complex
containing HSP70 and DNAJ/HSP40 (18)."
complex(p(HGNC:HSPH1),p(HGNC:DNAJB1),p(FPLX:HSPA)) -| path(MESH:"Protein Aggregation, Pathological")

SET Evidence = " HSP60 is essential for maturation and maintenance of the
mitochondrial proteome and is therefore intimately linked to energy production."
SET MeSHAnatomy = "Mitochondria"
p(HGNC:HSPD1) -> bp(HBP:Proteostasis)
p(HGNC:HSPD1) -- bp(MESH:"Energy Metabolism")
UNSET MeSHAnatomy

SET Evidence = " TRiC is
essential for proper posttranslational folding of the cytoskeletal components actin and
tubulin and is therefore essential for cell structure, division, and cargo delivery (11)."
p(FPLX:"CCT_complex") -- a(MESH:"Cellular Structures")
p(FPLX:"CCT_complex") -- bp(GO:"cell division")
p(FPLX:"CCT_complex") -- bp(GO:"intracellular transport")

SET Evidence = ". Proteins can be
degraded either individually or en masse by proteasomes (20) or lysosomes (21),
respectively. "
p(FPLX:Proteasome) -> bp(MESH:"Proteolysis")
a(MESH:Lysosomes) -> bp(MESH:"Proteolysis")

SET Evidence = " As discussed above, one approach is to employ specialized molecular chaperone
machines to release misfolded proteins from aggregates and direct them to the proteasome
for degradation (19)."
a(MESH:"Molecular Chaperones") -| path(MESH:"Protein Aggregation, Pathological")
p(FPLX:Proteasome) -| path(MESH:"Protein Aggregation, Pathological")

SET Evidence = " Alternatively, bulkier substrates, such as large inclusions, can be
directed to the lysosome, a membrane-bound organelle containing a host of nonspecific
proteases that can degrade a wide range of substrates (21). "
a(MESH:Lysosomes) -| path(MESH:"Protein Aggregation, Pathological")

SET Evidence = "Upon increased levels of nonnative proteins, HSF1 is released from its repressive complex,
acquires DNA-binding activity through homotrimerization, and rapidly translocates to the
nucleus to induce expression of genes encoding molecular chaperones (7, 35)."
bp(GO:"response to misfolded protein") -> act(p(HGNC:HSF1))
act(p(HGNC:HSF1)) -> tloc(p(HGNC:HSF1), MESH:"Cytosol", MESH:"Cell Nucleus")
tscript(p(HGNC:HSF1)) -> a(MESH:"Molecular Chaperones")

SET Evidence = "Once stress
has been relieved, HSF1 activity is repressed through acetylation and binding to molecular
chaperones (34, 36, 37)."
p(HGNC:HSF1, pmod(Ac)) -| act(p(HGNC:HSF1))
complex(p(HGNC:HSF1),a(MESH:"Molecular Chaperones")) -| act(p(HGNC:HSF1))

SET Evidence = " IRE1 is a transmembrane protein with kinase and endoribonuclease (RNase) activity
that senses misfolding in the ER directly, leading to autophosphorylation, oligomerization,
and acquisition of RNase activity (8)."
SET MeSHAnatomy = "Endoplasmic Reticulum"
bp(GO:"response to misfolded protein") -> kin(p(HGNC:ERN1))
kin(p(HGNC:ERN1)) -> p(HGNC:ERN1, pmod(Ph))
p(HGNC:ERN1, pmod(Ph)) -> act(p(HGNC:ERN1), ma(GO:"ribonuclease activity"))
UNSET MeSHAnatomy

SET Evidence = "This process allows active IRE1 to cleave XBP1
messenger RNA (mRNA), thereby generating a spliced transcript (XBP1s) that encodes a
stable form of XBP1 that binds DNA and induces transcription of UPR target genes (8)."
#UPR (unfolded protein response)
act(p(HGNC:ERN1), ma(GO:"ribonuclease activity")) -> p(HGNC:XBP1)
tscript(p(HGNC:XBP1)) -> bp(GO:"response to misfolded protein")

SET Evidence = " In
parallel, ER stress promotes the relocation of ATF6 from the ER membrane to the Golgi
apparatus, where it is cleaved by SP1 and SP2 proteases."
bp(MESH:"Endoplasmic Reticulum Stress") -> tloc(p(HGNC:ATF6), MESH:"Endoplasmic Reticulum", MESH:"Golgi Apparatus")
SET MeSHAnatomy = "Golgi Apparatus"
p(HGNC:PRSS1) -| p(HGNC:ATF6)
p(HGNC:PRSS2) -| p(HGNC:ATF6)
p(HGNC:PRSS1) -> p(HBP:"N-terminal fragment of ATF6")
p(HGNC:PRSS2) -> p(HBP:"N-terminal fragment of ATF6")
UNSET MeSHAnatomy

SET Evidence = "The cytosolic N-terminal fragment
of ATF6 that is generated translocates to the nucleus, binds DNA, and drives expression of a
complementary set of UPR genes (8)."
tloc(p(HBP:"N-terminal fragment of ATF6"), MESH:"Cytosol", MESH:"Cell Nucleus") -> tscript(p(HBP:"N-terminal fragment of ATF6"))
tscript(p(HBP:"N-terminal fragment of ATF6")) -> bp(GO:"response to misfolded protein")


SET Evidence = " Finally, a third ER transmembrane protein, PERK,
promotes translation of the TF ATF4 by phosphorylating the translation initiation factor
eIF2Î± in response to ER stress."
#PERK is EIF2AK3
bp(MESH:"Endoplasmic Reticulum Stress") -> kin(p(HGNC:EIF2AK3))
kin(p(HGNC:EIF2AK3)) -> p(HGNC:EIF2S1, pmod(Ph))
p(HGNC:EIF2S1, pmod(Ph)) -> tscript(p(HGNC:EIF2S1))
tscript(p(HGNC:EIF2S1)) -> p(HGNC:ATF4)

SET Evidence = " Under these conditions, ATF4 mRNA is preferentially
translated, leading to selective expression of the proapoptotic TF CHOP, which elicits
apoptosis if ER stress is not resolved, presumably to ensure that irreversibly damaged cells
are removed from the population."
#CHOP is DDIT3
p(HGNC:ATF4) -> p(HGNC:DDIT3)
p(HGNC:DDIT3) -> bp(GO:"apoptotic process")

SET Evidence = "Cerebellar granular neurons were found to express high levels of HSP70 in response to
mHTT expression but not mAtaxin-1."
SET Cell = "cerebellar granule cell"
p(HGNC:HTT, var("?")) -> p(FPLX:HSPA)
p(HGNC:ATXN1, var("?")) causesNoChange p(FPLX:HSPA)
UNSET Cell

SET Evidence = "Furthermore, increased levels of HSP70 were
found in the cerebellar cortex of human HD brain samples but not in tissue from unaffected
individuals or from brains of PD patients (57)."
SET MeSHAnatomy = "Cerebral Cortex"
p(FPLX:HSPA) positiveCorrelation path(MESH:"Huntington Disease")
UNSET MeSHAnatomy

SET Evidence = "Protein aggregation is recognized as a hallmark of neurodegenerative disease by the
consistent appearance of detergent-insoluble inclusions and aggregates in the nucleus and
cytoplasm of neurons."
SET MeSHAnatomy = "Neurons"
SET CellStructure = {"Cell Nucleus", "Cytoplasm"}
path(MESH:"Protein Aggregation, Pathological") -- path(MESH:"Neurodegenerative Diseases")
UNSET CellStructure
UNSET MeSHAnatomy

SET Evidence = "Studies of chaperone levels in tissue culture and mouse models of polyQ disease showed
that the levels of HSP70 (HSPA1A/B) and DNAJ/HSP40 (DNAJB1), as well as some
cochaperones, decline with protein aggregation (64, 65)."
path(MESH:"Protein Aggregation, Pathological") negativeCorrelation p(HGNC:HSPA1A)
path(MESH:"Protein Aggregation, Pathological") negativeCorrelation p(HGNC:HSPA1B)
path(MESH:"Protein Aggregation, Pathological") negativeCorrelation p(HGNC:DNAJB1)

SET Evidence = "Experiments examining the effects of AÎ² on
proteasomal activity in vitro revealed an inhibitory effect on the chymotrypsin-like
properties of the 20S core (73), consistent with observations of impaired proteasome
function in AD patient brains (74). "
a(CHEBI:"amyloid-beta") -| act(p(FPLX:Proteasome))
SET MeSHAnatomy = "Brain"
path(MESH:"Alzheimer Disease") negativeCorrelation act(p(FPLX:Proteasome))
UNSET MeSHAnatomy

SET Evidence = " Mice deficient for the autophagy-related genes
Atg5 and Atg7 exhibit severe neurodegeneration (84, 85), and the expression of disease-
associated proteins is reported to exert differential inhibitory effects on autophagic
pathways."
SET Species = "10090"
p(MGI:Atg5) -| bp(HP:Neurodegeneration)
p(MGI:Atg7) -| bp(HP:Neurodegeneration)
UNSET Species

SET Evidence = " Consistent with a role of autophagy in disease, AD patient tissues exhibit
impaired initiation of macroautophagy and an excess of autophagic vacuoles in dystrophic
neurites, possibly due to impaired targeting of the vacuolar ATPase to the lysosome (86, 87)."
path(MESH:"Alzheimer Disease") negativeCorrelation bp(GO:macroautophagy)

SET Evidence = "In contrast, Î±-synuclein overexpression impairs autophagy in mammalian cells and mice
through reduced expression of RAB1A, thereby inhibiting autophagosome formation (88). "
p(HGNC:SNCA) -| bp(GO:autophagy)
p(HGNC:SNCA) -| p(HGNC:RAB1A)
p(HGNC:RAB1A) -> bp(GO:"autophagosome assembly")

SET Evidence =  "In contrast to findings in HD, AD, and PD, a recent study has suggested that autophagy
is enhanced in ALS mice."
SET Species = "10090"
path(MESH:"Amyotrophic Lateral Sclerosis") -> bp(GO:autophagy)
UNSET Species

SET Evidence = " Reduced levels of lipofuscin, LC3, and p62 have been observed in
motor neurons of SOD1(G85R) mice (92). Treatment with the autophagy inhibitor chloroquine
restored lipofuscin, LC3, and p62 levels in motor neurons, suggesting that mutant SOD1
causes hyperactive autophagy in mice (92). "
#p62 is SQSTM1
SET Species = "10090"
SET Cell = "motor neuron"
p(HGNC:SOD1, var("p.Gly576Arg")) -| a(CHEBI:"N-retinylidene-N-retinylethanolamine")
p(HGNC:SOD1, var("p.Gly576Arg")) -| p(HGNC:MAP1LC3A)
p(HGNC:SOD1, var("p.Gly576Arg")) -| p(HGNC:SQSTM1)
a(CHEBI:chloroquine) -| bp(GO:autophagy)
a(CHEBI:chloroquine) -> a(CHEBI:"N-retinylidene-N-retinylethanolamine")
a(CHEBI:chloroquine) -> p(HGNC:MAP1LC3A)
a(CHEBI:chloroquine) -> p(HGNC:SQSTM1)
p(HGNC:SOD1, var("p.Gly576Arg")) -> bp(GO:autophagy)
UNSET Species

SET Evidence = " Disruption of the ATF6 arm of the
UPR(ER) is reported to occur in mouse models of HD and a VAPB cell model of ALS,
suggesting that differential changes in UPR arms may be a feature of disease progression
(102, 103). "
SET Species = "10090"
path(MESH:"Amyotrophic Lateral Sclerosis") negativeCorrelation p(HGNC:ATF6)
path(MESH:"Huntington Disease") negativeCorrelation p(HGNC:ATF6)
UNSET Species

SET Evidence = "Additionally, an investigation of chaperone and cochaperone gene expression in young
(36Â±4 years of age) and aged (73 Â±4 years of age) human brain tissue revealed that of 332
genes examined, 101 are significantly repressed with age, including HSP70, HSP40, HSP90,
and TRiC genes (113). Furthermore, 62 chaperone genes, including several small HSPs,
were found to be significantly induced, likely as a result of the cellular response to
accumulating protein damage with age (113)."
bp(MESH:Aging) -| p(FPLX:HSPA)
bp(MESH:Aging) -| p(FPLX:HSP90)
bp(MESH:Aging) -| p(HGNCGENEFAMILY:"DNAJ (HSP40) heat shock proteins")
bp(MESH:Aging) -> p(FPLX:HSPB)

SET Evidence = "Constitutive activation of
HSF1 is detrimental to cells and increased expression, and activity of HSF1 has been linked
to multiple forms of cancer, highlighting the need for appropriate and balanced activation of
stress response pathways as and when required throughout life (122)."
act(p(HGNC:HSF1)) -- path(MESH:Neoplasms)

SET Evidence = "As such, it is feasible that any reduction in the
protein degradation capacity of a cell could contribute to proteostasis collapse and promote
aging."
bp(HBP:Proteostasis) -| bp(MESH:Aging)

SET Evidence = "One strategy is to directly activate HSF1, thereby increasing the expression of multiple
molecular chaperones simultaneously. This approach has been traditionally achieved by
inhibition of HSP90 with compounds that bind the N-terminal ATP-binding pocket, such as
radicicol, geldanamycin, or 17-AAG (64, 132â134). "
#17-AAG is tanespimycin
act(p(FPLX:HSP90)) -| act(p(HGNC:HSF1))
a(CHEBI:radicicol) -| act(p(FPLX:HSP90))
a(CHEBI:geldanamycin) -| act(p(FPLX:HSP90))
a(CHEBI:tanespimycin) -| act(p(FPLX:HSP90))

SET Evidence = "High-throughput screens in yeast and HeLa cells identified HSF1A and F1, respectively, as
two small molecules that activate HSF1 independently of HSP90 inhibition (136, 137). "
#F1 compound number in figure. no name given
a(PUBCHEM:"377503130") -> act(p(HGNC:HSF1))

SET Evidence = "HSF1A suppresses toxicity in cell and tissue culture models of HD and SCA-3/MJD and
appears to activate HSF1 by impairing the activity of TRiC, a recently discovered negative
regulator of HSF1."
a(PUBCHEM:"377503130") -| act(p(FPLX:"CCT_complex"))
p(FPLX:"CCT_complex") -| act(p(HGNC:HSF1))

SET Evidence = "Treatment of cell, Drosophila, and mouse models of HD, SCA3/MJD, AD, PD, and ALS
with the mTOR inhibitor rapamycin (or a derivative) reduces aggregation and suppresses
disease (140â 143)."
#rapamycin is sirolimus
a(CHEBI:sirolimus) -| act(p(FPLX:mTORC1))
a(CHEBI:sirolimus) -| path(MESH:"Protein Aggregation, Pathological")
a(CHEBI:sirolimus) -| path(MESH:"Huntington Disease")
a(CHEBI:sirolimus) -| path(MESH:"Machado-Joseph Disease")
a(CHEBI:sirolimus) -| path(MESH:"Alzheimer Disease")
a(CHEBI:sirolimus) -| path(MESH:"Parkinson Disease")
a(CHEBI:sirolimus) -| path(MESH:"Amyotrophic Lateral Sclerosis")

SET Evidence = "An in silico screen based on the structure of 10-NCP, an Akt inhibitor that potently induces
autophagy (144), identified the molecules FPZ and MTM as potent activators of autophagic
flux and clearance of TDP-43 in mammalian cells (145)."
a(PUBCHEM:"10521421") -| act(p(FPLX:AKT))
a(PUBCHEM:"10521421") -> bp(GO:autophagy)
a(CHEBI:fluphenazine) -> bp(GO:autophagy)
a(CHEBI:methotrimeprazine) -> bp(GO:autophagy)
#TDP-43 is TARDBP
a(CHEBI:fluphenazine) -| p(HGNC:TARDBP)
a(CHEBI:methotrimeprazine) -| p(HGNC:TARDBP)

SET Evidence = "A screen for autophagy inducers in yeast identified the
molecules SMER-10, -18, and -28 as TOR-independent activators of autophagy (146). "
a(PUBCHEM:"799645") -> bp(GO:autophagy)
a(PUBCHEM:"877863") -> bp(GO:autophagy)
a(PUBCHEM:"1560402") -> bp(GO:autophagy)

SET Evidence = "Treatment of PC12 cells stably expressing mutant Î±-synuclein (A53T) with SMER-10, -18,
or-28 significantly reduced levels of mutant Î±-synuclein, an effect that was enhanced by
cotreatment with rapamycin (146)."
a(PUBCHEM:"799645") -| p(HGNC:SNCA, var("p.Ala53Thr"))
a(PUBCHEM:"877863") -| p(HGNC:SNCA, var("p.Ala53Thr"))
a(PUBCHEM:"1560402") -| p(HGNC:SNCA, var("p.Ala53Thr"))
composite(a(PUBCHEM:"799645"),a(CHEBI:sirolimus)) -| p(HGNC:SNCA, var("p.Ala53Thr"))
composite(a(PUBCHEM:"877863"),a(CHEBI:sirolimus)) -| p(HGNC:SNCA, var("p.Ala53Thr"))
composite(a(PUBCHEM:"1560402"),a(CHEBI:sirolimus)) -| p(HGNC:SNCA, var("p.Ala53Thr"))

SET Evidence = "In addition, SMER-10, -18, and -28 were effective at
suppressing mHTT aggregation and toxicity in COS-7 cells and flies (146)."
a(PUBCHEM:"799645") -| a(HBP:"huntingtin aggregates")
a(PUBCHEM:"877863") -| a(HBP:"huntingtin aggregates")
a(PUBCHEM:"1560402") -| a(HBP:"huntingtin aggregates")

SET Evidence = "The DUB
USP14 suppresses turnover of Tau and TDP-43 in mouse embryonic fibroblasts (MEFs) by
impairing the protea-some;"
SET CellLine = "MEF cell line"
p(HGNC:USP14) -| deg(p(HGNC:MAPT))
p(HGNC:USP14) -| deg(p(HGNC:TARDBP))
p(HGNC:USP14) -| act(p(FPLX:Proteasome))

SET Evidence = "Treatment with IU1 reduced
the levels of Tau, TDP-43, and ataxin-3 in MEFs in a USP14-dependent manner and
independently of changes in proteasome levels or composition (147)."
a(PUBCHEM:"675434") -| p(HGNC:MAPT)
a(PUBCHEM:"675434") -| p(HGNC:TARDBP)
a(PUBCHEM:"675434") -| p(HGNC:ATXN3)
a(PUBCHEM:"675434") -| act(p(HGNC:USP14))
a(PUBCHEM:"675434") causesNoChange p(FPLX:Proteasome)
UNSET CellLine
